Stanford

Vali Barsan

Instructor, Pediatrics - Hematology & Oncology

CLINICAL OFFICES

- **Pediatric Hematology Oncology**

  1000 Welch Rd Ste 300

  MC 5798

  Palo Alto, CA 94304

  Tel (650) 723-5535 **Fax** (650) 723-5231

Bio

BIO

Vali Barsan, MD is an Instructor in the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at Stanford University School of Medicine. Dr. Barsan obtained his BS in Bioengineering at UC San Diego Jacobs School of Engineering and then joined Illumina as an engineer to develop and optimize next generation sequencing tools. He earned his MD at Baylor College of Medicine where he studied the biology of cancer metastasis through molecular techniques in the Mani Lab at MD Anderson Cancer Center. Dr. Barsan completed residency in Pediatrics at UC San Diego and fellowship in Pediatric Hematology/Oncology at Stanford University. He is focused on developing and translating genomic technologies in oncology to implement personalized therapy and study mechanisms of effective cancer immunity.

CLINICAL FOCUS

- Pediatric Hematology-Oncology
- Cancer Immunology and Immunotherapy

ACADEMIC APPOINTMENTS

- Instructor, Pediatrics - Hematology & Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Anne T. and Robert M. Bass Endowed Fellow, Stanford Maternal and Child Health Research Institute (MCHRI) (2019 - 2021)

PROFESSIONAL EDUCATION

- Medical Education: Baylor College of Medicine (2015) TX
- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2021) CA
- Board Certification: Pediatrics, American Board of Pediatrics (2019)
- Residency, UC San Diego , Pediatrics (2018)
- Graduate Student Research, MD Anderson Cancer Center , Department of Translational Molecular Pathology, Mani Lab (2015)

- MD, Baylor College of Medicine (2015)
- BS, UC San Diego , Bioengineering (2009)

Research & Scholarship

RESEARCH INTERESTS

- Data Sciences
- Research Methods

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Adoptive T cell immunotherapy entails engineering immune cells to recognize cancer-specific antigens and target them for destruction. Barriers to efficacy can arise from both tumor antigen related as well as T cell related features. I am interested developing noninvasive molecular tools that enable us to understanding these relationships to improve the clinical application and development of cellular immunotherapeutics.

Publications

PUBLICATIONS

- **Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia.** *Science advances*
  Barsan, V., Xia, Y., Klein, D., Gonzalez-Pena, V., Youssef, S., Inaba, Y., Mahmud, O., Natarajan, S., Agarwal, V., Pang, Y., Autry, R., Pui, C. H., Inaba, et al
  2022; 8 (16): eabj1360
- **GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.** *Nature*
  Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, et al
  2022
- **Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, et al
  2021: JCO2003585
- **GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas.**
  Majzner, R. G., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggott, et al
  AMER ASSOC CANCER RESEARCH.2021
- **SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY**
  Mochizuki, A., Ramakrishna, S., Good, Z., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggot, et al
  OXFORD UNIV PRESS INC.2021: 39
- **GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG**
  Majzner, R., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Martin, A., Toland, et al
  OXFORD UNIV PRESS INC.2021: 49-50
- **GENERALIZABILITY OF POTENTIAL BIOMARKERS OF RESPONSE TO CTLA-4 AND PD-1 BLOCKADE THERAPY IN CANCER**
  Bortone, D., Vensko, S., Entwistle, S., Cogdill, A., Monette, A., Najjar, Y., Sweis, R., Tschernia, N., Wennerberg, E., Bommareddy, P., Haymaker, C., Khan, U., McGee, et al
  BMJ PUBLISHING GROUP.2020: A46–A47

- **CONSTRUCTION OF THE IMMUNE LANDSCAPE OF DURABLE RESPONSE TO CHECKPOINT BLOCKADE THERAPY BY INTEGRATING PUBLICLY AVAILABLE DATASETS**

  Rudqvist, N., Zappasodi, R., Wells, D., Thorsson, V., Cogdill, A., Monette, A., Najjar, Y., Sweis, R., Wennerberg, E., Bommareddy, P., Haymaker, C., Khan, U., McGee, et al

  BMJ PUBLISHING GROUP.2020: A5–A6

- **Prospects and Challenges for Use of CAR T Cell Therapies in Solid Tumors.** *Expert opinion on biological therapy*

  Ramakrishna, S., Barsan, V., Mackall, C.

  2020

- **Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.** *Current oncology reports*

  Barsan, V., Ramakrishna, S., Davis, K. L.

  2020; 22 (2): 11

- **Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.** *Journal for immunotherapy of cancer*

  Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K., Ziv, E., Chowell, D., Coussens, L. M., De Carvalho, et al

  2019; 7 (1): 131

- **Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience.** *Cureus*

  Barsan, V. n., Paul, M. n., Gorsi, H. n., Malicki, D. n., Elster, J. n., Kuo, D. J., Crawford, J. n.

  2019; 11 (12): e6281

- **NIVOLUMAB IN THE TREATMENT OF RECURRENT OR REFRACTORY PEDIATRIC BRAIN TUMORS: A SINGLE INSTITUTIONAL EXPERIENCE**

  Gorsi, H., Malicki, D., Khanna, P., Elster, J., Barsan, V., Tumblin, M., Yeh-Nayre, L., Milburn, M., Crawford, J.

  OXFORD UNIV PRESS INC.2018: 100

- **Primer on Cancer Immunotherapy and the Targeting of Native Proteins** *Early Phase Cancer Immunotherapy*

  Barsan, V., Tumeh, P.

  Springer.2018

- **Long-term follow-up and pregnancy after complete sacrectomy with lumbopelvic reconstruction: case report and literature review** *BMC PREGNANCY AND CHILDBIRTH*

  Barsan, V. V., Briceno, V., Gandhi, M., Jea, A.

  2016; 16: 1

- **A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome** *SCIENTIFIC REPORTS*

  Soundararajan, R., Paranjape, A. N., Barsan, V., Chang, J. T., Mani, S. A.

  2015; 5: 11766